Overexpression of c-met as a prognostic indicator for transitional cell carcinoma of the urinary bladder: A comparison with p53 nuclear accumulation

Journal of Clinical Oncology

Volumn 20, Issue 6, 2002, Pages 1544-1550

  Cheng, Hong Lin ^a   Trink, Barry ^a   Tzai, Tzong Shin ^a   Liu, Hsiao Sheng ^a   Chan, Shih Huang ^a   Ho, Chung Liang ^a   Sidransky, David ^a   Chow, Nan Haw ^a  

^a NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; PROTEIN P53; PROTEIN TYROSINE KINASE;

ARTICLE; BLADDER CARCINOMA; CANCER GRADING; CELL PROLIFERATION; DNA DAMAGE; DRUG ACCUMULATION; EPITHELIUM CELL; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MALIGNANT TRANSFORMATION; PRIORITY JOURNAL; PROGNOSIS; PROTO ONCOGENE; TRANSITIONAL CELL CARCINOMA; TUMOR SUPPRESSOR GENE; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; BLOTTING, NORTHERN; CARCINOMA, TRANSITIONAL CELL; CHI-SQUARE DISTRIBUTION; DISEASE PROGRESSION; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROTO-ONCOGENE PROTEINS C-MET; RNA, MESSENGER; SURVIVAL ANALYSIS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS;

EID: 0037087754     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.20.6.1544     Document Type: Article

References (43)

1. Growth factors: Regulation of normal and neoplastic growth
2. Tyrosine kinase receptor-activated signal transduction pathways which lead to oncogenesis
3. Hepatocyte growth factor/scatter factor induces a variety of tissue-specific morphogenic programs in epithelial cells
4. Expression of hepatocyte growth factor/scatter factor and its receptor, MET, suggests roles in human embryonic organogenesis
5. Hepatocyte growth factor/scatter factor-Met signaling in tumorigenicity and invasion/metastasis
6. "Invasive-growth" signaling by the Met/HGF receptor: The hereditary renal carcinoma connection
7. Expression of the Met/HGF receptor in normal and neoplastic human tissues
8. Met expression is associated with poor outcome in patients with axillary lymph node negative breast carcinoma
9. Expression of c-met is a strong independent prognostic factor in breast carcinoma
10. Clinical significance of hepatocyte growth factor and c-Met expression in extrahepatic biliary tract cancers
11. The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas
12. The relation between the growth patterns of gastric carcinoma and the expression of hepatocyte growth factor receptor (c-met), autocrine motility factor receptor, and urokinase-type plasminogen activator receptor
13. Tumor angiogenesis, hepatocyte growth factor, and c-Met expression in endometrial carcinoma
14. Expression of hepatocyte growth factor and its receptor c-met proto-oncogene in hepatocellular carcinoma
15. Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer
16. Overexpression of the met/HGF receptor in renal cell carcinomas
17. Expression of scatter factor in hmnan bladder carcinoma
18. Differential expression of hepatocyte growth factor in papillary and nodular tumors of the bladder
19. Tyrosine kinase profile of bladder cancer
20. The p53 tumour suppressor gene
21. Accumulation of nuclear p53 and tumor progression in bladder cancer
22. p53 expression predicts progression and poor survival in T1 bladder tumours
23. The influence of the level of lamina propria invasion and the prevalence of p53 nuclear accumulation on survival in stage T1 transitional cell bladder cancer
24. Cooperative effects of p53 and pRB alterations in primary superficial bladder tumors
25. The potential of soybean foods as a chemoprevention approach for human urinary tract cancer
26. The role of nm23-H1 in the progression of transitional cell bladder cancer
27. Gene structure of the human MET proto-oncogene
28. Novel mutations of the MET proto-oncogene in papillary renal carcinomas
29. The epidermal growth factor receptor and the prognosis of bladder cancer
30. C-met proto-oncogene expression in benign and malignant human renal tumors
31. Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC
32. Expression of hepatocyte growth factor (HGF)/scatter factor and its receptor c-MET correlates with poor prognosis in synovial sarcoma
33. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas
34. Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas
35. Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas
36. Uncoupling signal transducers from oncogenic MET mutants abrogates cell transformation and inhibits invasive growth
37. Two mutations affecting conserved residues in the Met receptor via different mechanisms
38. Mutant Met-mediated transformation is ligand-dependent and can be inhibited by HGF antagonists
39. Tumorigenic conversion of immortal human keratinocytes through stromal cell activation
40. Landscaping the cancer terrain
41. Over-expression of p53 nuclear oncoprotein in transitional-cell bladder cancer and its prognostic value
42. Immunohistochemical detection of p53 protein overexpression versus gene sequencing in urinary bladder carcinomas
43. Cell cycle regulators in bladder cancer: A multivariate survival study with emphasis on p27Kip1